Drug Name(s) PATANOL FDA Application No. (NDA) 020688 Active Ingredient(s) OLOPATADINE HYDROCHLORIDE Company ALCON Original Approval or Tentative Approval Date December 18, 1996 Chemical Type 1New molecular entity (NME) Review ... U.S. Food and Drug Administration, 1 month ago
THERAPEUTICS THE FOLLOWING TREATMENT OPTIONS CAN HELP YOU TAILOR TREATMENTS TO MEET SPECIFIC PATIENT NEEDS Patricia Fulmer, O.D., F.A.A.O., Huntsville, Ala. W ITH AS much as 40% of the population suffering from allergic conjunctivitis, it is one ...Optometric Management, 2 weeks ago
About the PTAB Life Sciences Report: Each week we will report on recent developments at the PTAB involving life sciences patents. Illumina, Inc. v. Scripps Research Institute PTAB Petition: IPR2016-01619; filed August 15, 2016 Patent at Issue: ...JD Supra, 3 weeks ago
(Before It's News) Temporary Tattoo Industry Summery The Global and Chinese Temporary Tattoo Industry, 2011-2021 Market Research Report is a professional and in-depth study on the current state of the global Temporary Tattoo industry with a ...Before It's News, 1 month ago
Argentum Pharmaceuticals and KVK Tech Succeed in Starting Patent Cancellation Trial Against Alcon's PAZEO®
NEW YORK , Aug. 1, 2016 /PRNewswire/ --The U.S. Patent & Trademark Office (PTO) granted a petition for inter partes review (IPR) filed by Argentum Pharmaceuticals LLC and its manufacturing partner KVK Tech, against all challenged claims of the sole ...WorldNetDaily, 1 month ago Argentum And KVK Tech Succeed In Starting Patent Cancellation Trial Against Alcon's PAZEO BioSpace, 1 month ago ARGENTUM PHARMACEUTICALS : and KVK Tech Succeed in Starting Patent Cancellation Trial Against Alcon's PAZEO® 4 Traders, 1 month ago
on your WebpageAdd Widget >Get your members hooked!